IL143555A0 - Method of administering a compound to multi-drug resistant cells - Google Patents

Method of administering a compound to multi-drug resistant cells

Info

Publication number
IL143555A0
IL143555A0 IL14355599A IL14355599A IL143555A0 IL 143555 A0 IL143555 A0 IL 143555A0 IL 14355599 A IL14355599 A IL 14355599A IL 14355599 A IL14355599 A IL 14355599A IL 143555 A0 IL143555 A0 IL 143555A0
Authority
IL
Israel
Prior art keywords
therapeutic compound
drug resistant
composition
administering
compound
Prior art date
Application number
IL14355599A
Other languages
English (en)
Original Assignee
Hadasit Med Res Service
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Med Res Service, Alza Corp filed Critical Hadasit Med Res Service
Publication of IL143555A0 publication Critical patent/IL143555A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14355599A 1998-12-18 1999-12-17 Method of administering a compound to multi-drug resistant cells IL143555A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11300498P 1998-12-18 1998-12-18
PCT/US1999/030230 WO2000035422A2 (fr) 1998-12-18 1999-12-17 Procede d'administration d'un compose a des cellules resistant a plusieurs medicaments

Publications (1)

Publication Number Publication Date
IL143555A0 true IL143555A0 (en) 2002-04-21

Family

ID=22347057

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14355599A IL143555A0 (en) 1998-12-18 1999-12-17 Method of administering a compound to multi-drug resistant cells

Country Status (12)

Country Link
US (2) US20040161457A1 (fr)
EP (1) EP1140022B8 (fr)
JP (1) JP2002532407A (fr)
AT (1) ATE385778T1 (fr)
AU (1) AU769569B2 (fr)
CA (1) CA2353593A1 (fr)
DE (1) DE69938148T2 (fr)
ES (1) ES2302391T3 (fr)
HK (1) HK1040633A1 (fr)
IL (1) IL143555A0 (fr)
MX (1) MXPA01006201A (fr)
WO (1) WO2000035422A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ014799A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
JP4922824B2 (ja) * 2000-04-03 2012-04-25 参天製薬株式会社 送達性物質およびそれを利用した薬物デリバリーシステム
EP1279406A4 (fr) * 2000-04-03 2007-10-24 Santen Pharmaceutical Co Ltd Transporteurs et systeme de distribution de medicament les utilisant
KR20050090987A (ko) * 2002-12-19 2005-09-14 알자 코포레이션 혈관신생 조직 성장 치료 방법
DK1592457T3 (da) 2003-01-27 2012-10-22 Endocyte Inc Folat-vinblastin-konjugat som lægemiddel
CN100423778C (zh) * 2003-11-25 2008-10-08 上海复旦张江生物医药股份有限公司 用于上载抗肿瘤药物的脂质体载体及其制备方法和应用
WO2006012527A1 (fr) 2004-07-23 2006-02-02 Endocyte, Inc. Groupes de liaison bivalents et conjugués de ceux-ci
WO2007130462A2 (fr) * 2006-05-04 2007-11-15 Alza Corporation Procédé de traitement des tumeurs micrométastatiques
NZ599239A (en) 2007-03-14 2013-10-25 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins
PT2308514E (pt) * 2007-03-23 2013-09-06 To Bbb Holding B V Conjugados para a administração orientada de medicamentos através da barreira hematoencefálica
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
AU2008268432B2 (en) 2007-06-25 2015-01-15 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
JP2011500835A (ja) 2007-10-25 2011-01-06 エンドサイト，インコーポレイテッド チューブリシン類および調製プロセス
US20120100206A1 (en) 2009-06-11 2012-04-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Targeted liposomes comprising n-containing bisphosphonates and uses thereof
US10085940B2 (en) 2011-07-13 2018-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Liposomes co-encapsulating a bisphosphonate and an amphipathic agent
US9393320B2 (en) 2011-12-07 2016-07-19 Universidade Do Minho Liposomes and its production method
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
GB201215289D0 (en) 2012-08-28 2012-10-10 Medical Res Council Nanoparticle formulation
US9950074B2 (en) * 2012-10-12 2018-04-24 Georg-August-Universität Göttingen Stiftung Öffenlichen Rechts, Universitätsmedizin Composition and delivery vehicle for active agents and methods therefor
CA2887727A1 (fr) 2012-10-16 2014-04-24 Endocyte, Inc. Conjugues d'administration de medicament contenant des acides amines artificiels et procedes d'utilisation
CN106420615B (zh) * 2016-07-05 2021-01-05 广东药科大学 一种靶向脂质体骨架材料及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US5858397A (en) * 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
US5804445A (en) * 1996-01-11 1998-09-08 Board Of Regents, The University Of Texas System High affinity mutants of nuclear factor-interleukin 6 and methods of use therefor
WO1998013072A1 (fr) * 1996-09-24 1998-04-02 Thomas Jefferson University Compositions et procedes destines au traitement de la resistance multiple aux anticancereux
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6162810A (en) * 1997-11-17 2000-12-19 The Regents Of The University Of California Inadone and tetralone compounds for inhibiting cell proliferation
US6426086B1 (en) * 1998-02-03 2002-07-30 The Regents Of The University Of California pH-sensitive, serum-stable liposomes
IT1315253B1 (it) * 1999-10-22 2003-02-03 Novuspharma Spa Preparazione liposomiale di 6,9-bis-(2-amminoetil)ammino|benzog|isochinolin-5,10-dione dimaleato
DK1684763T3 (da) * 2003-09-24 2008-09-01 Wyeth Corp 6-Aryl-7-halogen-imidazo(1,2-a)pyrimidiner som anticancermiddel

Also Published As

Publication number Publication date
MXPA01006201A (es) 2003-06-06
EP1140022B8 (fr) 2008-10-15
EP1140022B1 (fr) 2008-02-13
HK1040633A1 (en) 2002-06-21
DE69938148T2 (de) 2009-02-26
AU1940400A (en) 2000-07-03
ES2302391T3 (es) 2008-07-01
JP2002532407A (ja) 2002-10-02
EP1140022A2 (fr) 2001-10-10
AU769569B2 (en) 2004-01-29
ATE385778T1 (de) 2008-03-15
CA2353593A1 (fr) 2000-06-22
US20040161457A1 (en) 2004-08-19
WO2000035422A2 (fr) 2000-06-22
WO2000035422A3 (fr) 2000-10-12
US20060062842A1 (en) 2006-03-23
DE69938148D1 (de) 2008-03-27

Similar Documents

Publication Publication Date Title
EP1140022B8 (fr) Procede d'administration d'un compose a des cellules resistant a plusieurs medicaments
WO1998016202B1 (fr) Composition a base de liposomes fusogenes et procede correspondant
WO1999039741A3 (fr) Administration systemique de particules lipidiques du plasmide stables dans le serum en cancerotherapie
CA2193502A1 (fr) Sphingosomes servant a ameliorer l'administration de medicaments
WO2000045792A8 (fr) Preparations de particules hydrogel
ATE238039T1 (de) In liposomen eingeschlossene topoisomerase inhibitoren
WO2000007979A3 (fr) Composes et compositions pour l'administration de principes actifs
AU5408098A (en) Oral morphine multiparticulate formulation
WO2002022000A3 (fr) Therapie par particules alpha ciblees utilisant des conjugues d'actinium-225
CA2338358A1 (fr) Composes permettant de delivrer des agents actifs et compositions a base de ces composes
WO2001080843A3 (fr) Inhibition d'une proliferation cellulaire anormale avec de la camptothecine et combinaisons contenant ledit compose
UA50719C2 (uk) Проліки для терапії пухлин і запальних захворювань
WO2002013843A3 (fr) Agents chimiotherapeutiques conjugues avec p97, et leurs utilisations pour le traitement des tumeurs neurologiques
CA2628857A1 (fr) Preparation et methode de traitement de neoplasmes par inhalation
EP1698629A3 (fr) Polyamines et leur utilisation en therapie
CA2122519A1 (fr) Traitement du cancer et prevention des metastases
CA2208206A1 (fr) Composition pour le traitement de tumeurs comprenant du lactose et un conjugue saccharidique d'un compose phenolique cytotoxique
CA2202531A1 (fr) Lyophilisat de complexe lipide de camptothecines non hydrosolubles
JP2002532407A5 (fr)
WO1999022722A3 (fr) Utilisation de macrolides pour le traitement du cancer et de la degenerescence maculaire
CA2108963A1 (fr) Compositions et methodes de traitement et de prevention du cancer, du sida et de l'anemie
WO1998030709A3 (fr) Promedicaments non immunogenes et marqueurs capables d'etre selectionnes s'utilisant en therapie genique
Sharma et al. Modulation of human ovarian tumor cell sensitivity to N-(phosphonacetyl)-L-aspartate (PALA) by liposome drug carriers
CA2225807A1 (fr) Utilisation d'alcaloides de la classe lamellarine dans des procedes de traitement
ATE356637T1 (de) Supramolekulare komplexe enthaltende arzneimittel